PRIVATE medical insurance premiums could snowball when cancer drug Herceptin is licensed for use within the NHS, warns a leading consultant.
Most insurers are expected to extend their cover to include the drug treatment – unless specific exclusions are made – although PMI costs will increase by up to £25,000 for each employee treated. ...
To continue reading this article...
Join Professional Pensions
- Unlimited access to real-time news, analysis and opinion from the industry
- Receive our in-depth monthly magazine in either print or digital format
- Access our Sustainable Investment Hub covering news and opinion from thought leaders in the ESG space
- Receive important and breaking news stories selected by the Editors in our daily newsletter
- Hear from industry experts and other forward-thinking leaders
- Receive a monthly members-only newsletter with exclusive opinion pieces from leading industry experts and a feature from the magazine in advance of its release date